Valuation: OliX Pharmaceuticals, Inc

Market Cap 2,735B 1.78B 1.56B 1.44B 1.35B 2.53B 168B 2.58B 17.33B 6.7B 83.16B 6.7B 6.55B 288B P/E 2026 *
-87x
P/E 2027 * -89.4x
Enterprise Value 2,735B 1.78B 1.56B 1.44B 1.35B 2.53B 168B 2.58B 17.33B 6.7B 83.16B 6.7B 6.55B 288B EV / Sales 2026 *
342x
EV / Sales 2027 * 249x
Free-Float
82.92%
Yield 2026 *
-
Yield 2027 * -
06-04 OliX Pharmaceuticals, Inc announced that it has received KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
06-01 OliX Pharmaceuticals, Inc announced that it expects to receive KRW 110.758162833 billion in funding from Business Opportunities for L'Oréal Development, Weiss Asset Management LP CI
05-15 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-01 Ollix Receives Patent Registration Decision from the United States Patent and Trademark Office CI
03-16 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-08 Vect-Horus Reports CNS-Focused Research Collaboration with OliX Pharmaceuticals CI
12-02 Olix Pharmaceuticals receives milestone payment from L'Oréal RE
11-14 OliX Pharmaceuticals, Inc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
28/08/25 OliX Pharmaceuticals, Inc announced that it has received KRW 115.002040047 billion in funding from a group of investors CI
14/08/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
15/05/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
21/03/25 OliX Pharmaceuticals, Inc Reports Earnings Results for the Full Year Ended December 31, 2024 CI
10/02/25 Lilly, South Korean Drug Maker Partnering to Commercialize Prospective Liver Disease Treatment MT
1 day-4.34%
1 week+1.97%
Current month-23.13%
1 month-24.04%
3 months-32.87%
6 months-0.15%
Current year-4.13%
1 week 119,100
Extreme 119100
150,600
1 month 112,000
Extreme 112000
188,100
Current year 111,800
Extreme 111800
217,000
1 year 34,500
Extreme 34500
217,000
3 years 8,280
Extreme 8280
217,000
5 years 8,280
Extreme 8280
217,000
10 years 8,280
Extreme 8280
217,000
Manager TitleAgeSince
Chief Executive Officer 54 01/02/2010
Director of Finance/CFO 40 -
Corporate Officer/Principal 51 28/03/2022
Director TitleAgeSince
Director/Board Member 59 28/03/2022
Director/Board Member 53 29/03/2021
Chairman 54 01/02/2010
Date Insider Type Main position Quantity % Market Cap.
28/02/25Fiscal year

Director

30,000 0.1625%
28/02/25Fiscal year

Chief Technology Officer

8,000 0.0433%
Change 5-day change 1-year change 3-year change Capi.($)
-4.34%+1.97%+269.78%+711.33% 1.78B
+0.33%+1.37%+63.66%+126.38% 55.63B
+0.82%+15.05%+79.52%+85.53% 52.25B
+1.36%+0.36%-14.52%-13.83% 23.07B
-1.04%+7.91%+3.91%+417.68% 22.41B
-0.18%+7.20%+31.37%-13.62% 17.32B
-1.10%+4.00%+29.97%-33.36% 15.94B
+2.89%+5.51%+25.42%+186.30% 13.77B
-3.35%+8.96%+134.32%+289.59% 13.47B
+1.31%+0.53%+27.83% - 12.43B
Average -0.33%+4.60%+65.13%+195.11% 22.81B
Weighted average by Cap. +0.23%+5.12%+50.23%+127.55%

Financials

2026 *2027 *
Net sales 8B 5.22M 4.57M 4.22M 3.95M 7.4M 492M 7.55M 50.67M 19.61M 243M 19.59M 19.16M 843M 11B 7.17M 6.29M 5.8M 5.43M 10.18M 677M 10.39M 69.67M 26.96M 334M 26.93M 26.34M 1.16B
Net income -31B -20.21M -17.72M -16.34M -15.29M -28.68M -1.91B -29.28M -196M -75.98M -942M -75.9M -74.24M -3.27B -30B -19.56M -17.15M -15.81M -14.8M -27.75M -1.85B -28.33M -190M -73.53M -912M -73.45M -71.85M -3.16B
Net Debt - -
Logo OliX Pharmaceuticals, Inc
OliX Pharmaceuticals, Inc. is a Korea-based company principally engaged in the research and development of new drugs for intractable diseases based on ribonucleic acid interference (RNAi) platform technologies. The Company’s product profile consists of OLX101, OLX102, OLX103, OLX104, OLX201, OLX301, OLX401 and others. These products are used for the treatment of hypertrophic scars and keloids, atopic dermatitis, androgenic alopecia, diabetic ulcer, age-related macular degeneration (AMD), idiopathic pulmonary fibrosis, neuropathic pain, liver fibrosis. In addition, these products are applied for skin brightening, anti-wrinkle and others. The Company operates its business within domestic market and to overseas markets.
Employees
-
Date Price Change Volume
26/06/26 ₩134,600.00 -4.34% 300,629
25/06/26 ₩140,700.00 +1.66% 290,354
24/06/26 ₩138,400.00 +13.91% 434,117
23/06/26 ₩121,500.00 -7.04% 186,897
22/06/26 ₩130,700.00 -0.98% 232,761
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A226950 Stock